ISRCTN42412334
Completed
Not Applicable
Phase II study: investigation of the safety and efficacy of a protocol for tight glycaemic control in patients with chronic obstructive pulmonary disease (COPD) exacerbations admitted to an acute medical unit
St George's, University of London (UK)0 sites20 target enrollmentNovember 20, 2008
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
- Sponsor
- St George's, University of London (UK)
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Physician diagnosis of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) as primary cause for admission
- •2\. Able to enter study within 24 hours of admission
- •3\. Age greater than 40 years, male and female
Exclusion Criteria
- •1\. Intensive care unit admission
- •2\. Moribund or not for active treatment
- •3\. Admission expected to last less than 48 hours
- •4\. Unable or unwilling to give informed consent
- •5\. Known type I diabetes mellitus
- •6\. Patients with reduced awareness of hypoglycaemia including reduced Glasgow Coma Scale or those taking beta blockers
- •6\. Patients with renal or hepatic failure at increased risk of hypoglycaemia
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Phase II study to evaluate the safety and the efficacy of CBD (Bortezomib, Cyclophosphamide, Dexamethasone) regimen for the patients with relapsed and/or refractory multiple myelomarelapsed and/or refractory multiple myelomaJPRN-UMIN000003076ara Hospital Kinki University School Of Medicine20
Not yet recruiting
Phase 2
A Phase II Study to Investigate the Safety and efficacy of APC201 for the Treatment of Pain Associated with Osteoarthritis of the KneeACTRN12623000273684Andros Pharmaceuticals Pty Ltd60
Completed
Phase 2
A clinical trial to study the safety and efficacy of a monoclonal antibody in patients with active psoriasisCTRI/2008/091/000296Biocon Limited
Active, not recruiting
Phase 2
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 in hand and foot skin reaction in Cancer Patients.Health Condition 1: L271- Localized skin eruption due to drugs and medicaments taken internallyCTRI/2023/01/048670OnQuality Pharmaceuticals (USA) LLC
Not yet recruiting
Phase 2
Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR inhibitor-Associated HFSR in Cancer Patients.Health Condition 1: L271- Localized skin eruption due to drugs and medicaments taken internallyCTRI/2021/07/034694ONQUALITY PHARMACEUTICALS USA LLC